Zynex (OTCMKTS:ZYXI) announced its quarterly earnings data on Tuesday. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.01, MarketWatch Earnings reports. The business had revenue of $8.13 million for the quarter, compared to the consensus estimate of $7.96 million. Zynex had a net margin of 33.49% and a return on equity of 205.15%.
OTCMKTS:ZYXI traded down $0.04 during trading hours on Wednesday, reaching $3.40. 2,300 shares of the company were exchanged, compared to its average volume of 15,393. Zynex has a 52-week low of $1.10 and a 52-week high of $5.50. The company has a market cap of $104.50 million, a P/E ratio of 15.45 and a beta of 0.95.
A number of equities analysts have weighed in on the stock. ValuEngine downgraded shares of Zynex from a “hold” rating to a “sell” rating in a research note on Tuesday, October 2nd. B. Riley set a $7.00 price target on shares of Zynex and gave the stock a “buy” rating in a research note on Friday, November 2nd. Finally, Zacks Investment Research downgraded shares of Zynex from a “hold” rating to a “sell” rating in a research note on Friday, August 10th.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Further Reading: When is a capital gain realized?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.